Healthy Bioequivalence study Dapagliflozin Pharmacokinetics Metformin Pharmacokinetics
Conditions
Interventions
Experimental Drug,Active Comparator Drug
Sponsors
Sun Pharmaceutical Industries Ltd.
Ranbaxy (Thailand) Co., Ltd.
Eligibility
Sex/Gender
All
Age
15 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Thai Male/Female must be 18-55 years of age, BMI = 18.0-30.0 kg/m2, inclusive. 2. Must be in good health as determined by medical history, vital signs (blood pressure (systolic blood pressure not lower than 90 and not over 139 mmHg, diastolic blood pressure not lower than 60 and not over 89 mmHg), body temperature, pulse rate and respiratory rate) and physical examination or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians 3. Screening ECG without clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians 4. Screening visit laboratory values of blood test including hematology (CBC with differential), FBS, BUN, Cr and liver function test (AST, ALT, total bilirubin and ALP) must be within the normal range or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians. 5. Urinalysis results within normal limit or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians 6. Must have serum HBsAg, anti-HCV and anti-HIV negative 7. Female subject must have serum beta-hCG within normal range of non-pregnant woman or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians. 8. Female subject of childbearing potential or male subject agrees to use an acceptable birth control method from Screening Visit to Follow-up Visit. The acceptable birth control method is defined as a barrier method of contraception (including condoms, intrauterine device and diaphragm with spermicidal agent) or total abstinence from sexual intercourse from Screening Visit to Follow-up Visit. Hormonal contraceptives are not acceptable. 9. Female subject of non-childbearing potential (hysterectomy, both ovaries removed, surgically sterilized or postmenopausal (for at least 12 consecutive months of amenorrhea)) 10. Female subject must agree not to become pregnant for the entire participation period and must have a negative result for a urine pregnancy test performing prior to dosing at each period. 11. Non-smoker (never smoked or no smoking within the previous 1 year as judged by medical history) 12. Refrain from using herbal medications, cannabis containing products, dietary supplements (e.g., St. Johns Wort, ginkgo biloba, garlic supplements), vitamins, grapefruit or grapefruit juice, or pomelo within 14 days before the first dose administration of investigational product (Day 1). Subjects must agree to refrain from these items until the last collection time point of Period 2. 13. Subject must have ended any systemic medications or any medications that have any impact on gastrointestinal system at least 30 days prior to Day 1 or at least 7 times of elimination t1/2 prior to Day 1 and agree to continue their refraining throughout the follow-up period. 14. Subject must refrain from any food and beverages containing xanthenes, caffeine and alcohol for at least 72 hours prior to Day 1 and agree to continue their refraining throughout the last collection time point of Period 2. 15. Have the ability to understand the requirements of the study and must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific pr
Exclusion criteria
Exclusion criteria: 1. Known hypersensitivity to dapagliflozin or metformin hydrochloride or any other similar class of drugs or its components 2. Past medical history of renal and hepatic insufficiency 3. Subject has a history of any illness that, in the opinion of Principal/Clinical Investigator or designated physicians, might confound the result of the study or pose an additional risk in administering investigational product to the subject. This may include but is not limited to: a history of relevant drug or food allergies; history or evidence of cardiovascular, gastrointestinal, central nervous system disease, chronic respiratory disease, renal and hepatic impairment and glaucoma; history or presence of clinically significant illness; or history of mental illness that may affect compliance with study requirements. 4. Have a history of serious urinary tract infections including urosepsis and pyelonephritis or genital mycotic infections 5. Have history of drug abuse (in the opinion of Principal/Clinical Investigator or designated physicians, as judged by medical history) in the last 12 months 6. Have positive results of urine drug abuse test on opioids (Mor, MTD), cannabinoids (THC), Meth, Coc, BZD or MDMA at Screening Visit or before dose administration of each period 7. Alcohol abuse or excessive use (in the opinion of Principal/Clinical Investigator or designated physicians, as judged by medical history) in the last 12 months 8. Have positive result of alcohol breathing test at Screening Visit or before dose administration of each period 9. Female subject is pregnant or breast feeding. 10. Difficulties fasting or consuming standard high-fat, high-calorie meal or standard meals 11. Difficulties swallowing whole tablet 12. Donation or loss of whole blood: a. from 50 mL to 499 mL within 30 days prior to Day 1 b. 500 mL or more within 56 days prior to Day 1 13. Participation in any investigational drug study within 30 days from Screening Visit (from the last Follow-up Visit of the previous study to Screening Visit of this study)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cmax 0.000, 0.167, 0.333, 0.667, 1.000, 1.500, 2.000, 2.500, 3.000, 3.500, 4.000, 5.000, 6.000, 7.000, 8.000, 9.000, 10.000, 11.000, 12.000, 14.000, 16.000, 24.000, 36.000 and 48.000 hours post-dose Dapagliflozin in plasma,AUC 0.000, 0.167, 0.333, 0.667, 1.000, 1.500, 2.000, 2.500, 3.000, 3.500, 4.000, 5.000, 6.000, 7.000, 8.000, 9.000, 10.000, 11.000, 12.000, 14.000, 16.000, 24.000, 36.000 and 48.000 hours post-dose Dapagliflozin in plasma,Cmax 0.000, 0.167, 0.333, 0.667, 1.000, 1.500, 2.000, 2.500, 3.000, 3.500, 4.000, 5.000, 6.000, 7.000, 8.000, 9.000, 10.000, 11.000, 12.000, 14.000, 16.000, 24.000, 36.000 and 48.000 hours post-dose Metformin in plasma,AUC 0.000, 0.167, 0.333, 0.667, 1.000, 1.500, 2.000, 2.500, 3.000, 3.500, 4.000, 5.000, 6.000, 7.000, 8.000, 9.000, 10.000, 11.000, 12.000, 14.000, 16.000, 24.000, 36.000 and 48.000 hours post-dose Metformin in plasma | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety - Overall safety monitoring | — |
Countries
Thailand
Contacts
Public ContactAriya Khunvichai
Medica Innova Co., Ltd.
Outcome results
None listed